Long-Term Safety of Semaglutide and Tirzepatide: 2025 Updates
Long-term safety review for semaglutide and tirzepatide covering current label warnings, ongoing monitoring questions, and how to interpret major outcome data more carefully.
More on Safety & Monitoring
Evidence Summary
This article summarizes current prescribing information and major published outcome data for semaglutide and tirzepatide. Use it as a monitoring guide rather than as a promise that every rare-event question is fully settled.
What We Know from Extended Studies
STEP Extension Studies (Semaglutide)
Longer semaglutide follow-up data supports a familiar pattern:
- Weight loss can be sustained while treatment continues, although results vary by patient and adherence
- No dominant new long-term safety signal has displaced the known label warnings
- Gastrointestinal side effects are still the most common issue and often improve after the escalation period
SURMOUNT Extension Studies (Tirzepatide)
Tirzepatide follow-up data points in a similar direction:
- Weight loss can continue through the longer treatment period before stabilizing
- The safety profile is still dominated by GI tolerability and the same need for escalation caution
- Long-term cardiovascular outcome questions are still developing alongside broader post-marketing experience
Key Safety Concerns and Current Evidence
Thyroid Cancer Risk
Animal Studies: Rodent studies showed thyroid C-cell tumors at high doses.
Human Data: Current labeling says it is unknown whether these medicines cause thyroid C-cell tumors in humans. The boxed warning remains because of the rodent findings, not because a human causal link has been proven.
Recommendation: Avoid in patients with personal/family history of medullary thyroid carcinoma or MEN2.
Pancreatitis
Known issue: Acute pancreatitis has been reported in trials and post-marketing use, even though it appears to be uncommon overall.
What this means: Severe persistent abdominal pain should not be treated like routine nausea, and clinicians typically stop the medication while pancreatitis is being evaluated.
Recommendation: Stop medication and seek care for severe abdominal pain. Monitor high-risk patients.
Gallbladder Disease
Mechanism: Rapid weight loss increases cholesterol concentration in bile, promoting gallstone formation.
Label context: Acute gallbladder disease has been reported in product labeling and can overlap with the physiologic effects of rapid weight loss.
Prevention: Adequate hydration, gradual dose titration, and prompt evaluation of right-upper-quadrant pain or fever are more reliable than trying to predict risk perfectly.
Neuropsychiatric Effects (Under Investigation)
Emerging Signal: Mood-related adverse-event reports continue to be monitored by regulators.
Current Status: A causal relationship has not been established, but mental-health changes should still be taken seriously and discussed with a clinician.
Recommendation: Monitor mood changes, especially in patients with psychiatric history.
2025 Regulatory Updates
Current Prescribing Information Themes
- • Ongoing attention to pancreatitis, gallbladder disease, dehydration, and kidney injury risk
- • Delayed gastric emptying remains relevant for oral-drug timing and procedure planning
- • Patients should tell anesthesia and surgical teams they use a GLP-1 medication before planned procedures
- • Current product labeling should be checked directly because wording can change over time
EMA Safety Committee Review
- • European regulators have continued reviewing mood-related reports and other emerging safety questions
- • Safety monitoring has not overturned the overall benefit-risk profile for indicated patients
- • Pharmacovigilance findings should be interpreted alongside formal prescribing information and patient-specific risk factors
Reassuring Safety Data
Cardiovascular Safety
SELECT reported cardiovascular benefit with semaglutide in adults with overweight or obesity and established cardiovascular disease, which is part of why long-term GLP-1 discussions should include benefits as well as risks.
Kidney Protection
FLOW added evidence that semaglutide can support kidney outcomes in an appropriate chronic-kidney-disease population with type 2 diabetes, reinforcing that long-term decisions should weigh potential benefit and risk together.
Frequently Asked Questions
Is it safe to take semaglutide or tirzepatide long-term?
Long-term use can be appropriate for many patients when the benefits continue to outweigh the risks, but it still requires ongoing monitoring and reassessment. The best answer depends on the indication, side-effect profile, comorbidities, and whether the patient is still tolerating treatment well.
What are the main long-term concerns with GLP-1 medications?
Key concerns include the boxed-warning context from rodent thyroid findings, pancreatitis warning signs, gallbladder disease, dehydration or kidney issues, and procedure-related questions tied to delayed gastric emptying. Long-term safety discussions should also address nutrition, lean-mass preservation, and when symptoms warrant escalation.
Has the FDA issued any new warnings for GLP-1s in 2025?
Patients should check the current prescribing information rather than relying on one static summary, because label language and safety communications can evolve. Recent discussions have focused on delayed gastric emptying, procedure planning, GI complications, and other adverse-event monitoring questions.
Should I get regular tests while on GLP-1 medications?
Monitoring should be individualized, but many patients need periodic review of weight trend, hydration, tolerability, blood pressure, and labs relevant to their underlying condition. The specific testing plan depends on why the medication is being used and what risk factors the patient has.
Get Safe, Monitored GLP-1 Treatment
Our medical team provides comprehensive monitoring and ongoing safety oversight for your GLP-1 therapy.
Start with Medical SupervisionSources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication or treatment program.